TheraRadar
← Back
Data updated: Mar 29, 2026

ZHEJIANG

OncologyDermatologyCardiovascular
Generics

ZHEJIANG is a generic drug manufacturer focused on Oncology, Dermatology, Cardiovascular.

2012
Since
1
Drugs
-
Trials
11
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

SUMATRIPTAN SUCCINATE 2025-11-06
SUMATRIPTAN SUCCINATE 2025-10-21
Labeling
SUMATRIPTAN SUCCINATE 2025-07-25
Labeling
SUMATRIPTAN SUCCINATE 2025-07-15
SUMATRIPTAN SUCCINATE 2025-03-28
Manufacturing (CMC)
SUMATRIPTAN SUCCINATE 2025-03-17
Manufacturing (CMC)
SUMATRIPTAN SUCCINATE 2024-12-31
SUMATRIPTAN SUCCINATE 2024-12-12
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 56%
0 drugs Phase 3: 2 Phase 2: 7 Phase 1: 19
Dermatology 21%
0 drugs Phase 3: 3 Phase 2: 1 Phase 1: 1
Cardiovascular 12%
0 drugs Phase 3: 2 Phase 1: 1
Immunology 5%
0 drugs Phase 3: 1
Infectious Disease 5%
0 drugs Phase 1: 4

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Infectious Disease, Dermatology, Immunology
COSETTE other
Cardiovascular, Dermatology, Infectious Disease, Immunology, Oncology
Merck big-pharma
Oncology, Infectious Disease, Cardiovascular, Immunology
Baxter specialty
Infectious Disease, Cardiovascular, Oncology, Dermatology
Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease, Cardiovascular